Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci186291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Baoyu He und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine. Hauptthemen laut MEDLINE: Lysophospholipids, Sphingosine, Neovascularization, Pathologic, Receptors, OX40. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Understanding the complexity of the tumor microenvironment is vital for improving immunotherapy outcomes. Here, we report that the T cell costimulatory molecule OX40 was highly expressed in tumor endothelial cells (ECs) and was negatively associated with the prognosis of patients, which is irrelevant to T cell activation. Analysis of conditional OX40 loss- and gain-of-function transgenic mice showed that OX40 signal in ECs counteracted the antitumor effects produced in T cells by promoting angiogenesis. Mechanistically, leucine-rich repeat–containing GPCR5 (Lgr5 + ) cancer stem cells induced OX40 expression in tumor ECs via EGF/STAT3 signaling. Activated OX40 interacted with Spns lysolipid transporter 2 (Spns2), obstructing the export of sphingosine 1-phosphate (S1P) and resulting in S1P intracellular accumulation. Increased S1P directly bound to Yes 1–associated protein (YAP), disrupting its interaction with large tumor suppressor kinase 1 (LATS1) and promoting YAP nuclear translocation. Finally, the YAP inhibitor verteporfin enhanced the antitumor effects of the OX40 agonist. Together, these findings reveal an unexpected protumor role of OX40 in ECs, highlighting the effect of nonimmune cell compartments on immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine.
- Department of Gastrointestinal Surgery, and.
- Department of Oncology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
- Department of Central Lab, Weihai Municipal Hospital, Shandong University, Weihai, Shandong, China.
- Institute of Immunology and Molecular Medicine, Jining Medical University, Jining, Shandong, China.
- Shanghai Cancer Center, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Taishan Scholar Foundation of Shandong Province
- Natural Science Foundation of Shandong Province
Zitieren
APA
He, B., Zhao, R., Zhang, B., Pan, H., Liu, J., Huang, L., Wei, Y., Yang, D., Liang, J., Wang, M., Zhao, M., Wang, S., Dong, F., Zhang, J., Zhang, Y., Zhang, X., Zhang, X., Dong, G., Xiong, H., …, & Zhang, B. (2025). Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis. Journal of Clinical Investigation. https://doi.org/10.1172/jci186291
Vancouver
He B, Zhao R, Zhang B, Pan H, Liu J, Huang L, et al. Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis. Journal of Clinical Investigation. 2025. doi:10.1172/jci186291
BibTeX
@article{He2025,
author = {He, Baoyu and Zhao, Rou and Zhang, Baogui and Pan, Hongli and Liu, Jilan and Huang, Lunhua and Wei, Yingying and Yang, Dong and Liang, Jing and Wang, Mingyi and Zhao, Mingsheng and Wang, Sen and Dong, Fengyun and Zhang, Junfeng and Zhang, Yanhua and Zhang, Xu and Zhang, Xiao and Dong, Guanjun and Xiong, Huabao and Bie, Qingli and Zhang, Bin},
title = {Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci186291}
}
EUVIMED